Sanofi Announces Mixed Results from Phase 3 Studies of Itepekimab for COPD Treatment
I'm PortAI, I can summarize articles.
Sanofi SA has reported mixed results from its phase 3 studies of itepekimab for treating chronic obstructive pulmonary disease (COPD) in former smokers. The AERIFY-1 study achieved its primary endpoint with a significant reduction in exacerbations, while the AERIFY-2 study did not meet its primary endpoint despite some earlier benefits. Itepekimab was well tolerated in both studies. Sanofi, in collaboration with Regeneron, is evaluating the data and plans to discuss results with regulatory authorities. The drug is also being assessed for other conditions, including chronic rhinosinusitis and bronchiectasis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments